Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy

Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy

The urine lipoarabinomannan (LAM) antigen test is a TB diagnostic test with highest sensitivity in individuals with advanced HIV. Its role in TB diagnostic algorithms for HIV positive outpatients remains unclear. ACTG A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2021-02
Hauptverfasser: Matoga, Mitch M, Bisson, Gregory P, Gupta, Amita, Miyahara, Sachiko, Sun, Xin, Fry, Carrie, Manabe, Yukari C, Kumwenda, Johnstone, Cecilia, Kanyama, Nyirenda, Mulinda, Ngongondo, McNeil, Mbewe, Abineli, Lagat, David, Wallis, Carole, Mugerwa, Henry, Hosseinipour, Mina C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Clinical infectious diseases
container_volume
creator Matoga, Mitch M
Bisson, Gregory P
Gupta, Amita
Miyahara, Sachiko
Sun, Xin
Fry, Carrie
Manabe, Yukari C
Kumwenda, Johnstone
Cecilia, Kanyama
Nyirenda, Mulinda
Ngongondo, McNeil
Mbewe, Abineli
Lagat, David
Wallis, Carole
Mugerwa, Henry
Hosseinipour, Mina C
description The urine lipoarabinomannan (LAM) antigen test is a TB diagnostic test with highest sensitivity in individuals with advanced HIV. Its role in TB diagnostic algorithms for HIV positive outpatients remains unclear. ACTG A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen negative HIV positive adults initiating ART with CD4 counts
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_33638976</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33638976</sourcerecordid><originalsourceid>FETCH-pubmed_primary_336389763</originalsourceid><addsrcrecordid>eNqFjssKgkAYRocg0i6vEP8LCMrgbWlhGBRETG1l0rH-0HGYUcG3r6DWrT445yy-CbE9n4ZO4MeeRebGPF3X8yLXnxGL0oBGcRjY5HzRKAUckiMwYTqUd0AJSTlwWYgSsv0VTq3BDgfxpn3dmY_nwDTyGtoK0kahxgLYBthDaK7GJZlWvDZi9d0FWe9Sts0c1d8aUeZKY8P1mP9O0L_BCzYQOwE</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Matoga, Mitch M ; Bisson, Gregory P ; Gupta, Amita ; Miyahara, Sachiko ; Sun, Xin ; Fry, Carrie ; Manabe, Yukari C ; Kumwenda, Johnstone ; Cecilia, Kanyama ; Nyirenda, Mulinda ; Ngongondo, McNeil ; Mbewe, Abineli ; Lagat, David ; Wallis, Carole ; Mugerwa, Henry ; Hosseinipour, Mina C</creator><creatorcontrib>Matoga, Mitch M ; Bisson, Gregory P ; Gupta, Amita ; Miyahara, Sachiko ; Sun, Xin ; Fry, Carrie ; Manabe, Yukari C ; Kumwenda, Johnstone ; Cecilia, Kanyama ; Nyirenda, Mulinda ; Ngongondo, McNeil ; Mbewe, Abineli ; Lagat, David ; Wallis, Carole ; Mugerwa, Henry ; Hosseinipour, Mina C</creatorcontrib><description>The urine lipoarabinomannan (LAM) antigen test is a TB diagnostic test with highest sensitivity in individuals with advanced HIV. Its role in TB diagnostic algorithms for HIV positive outpatients remains unclear. ACTG A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen negative HIV positive adults initiating ART with CD4 counts &lt;50 cells/µL. Retrospective LAM testing was performed on stored urine obtained at baseline. We determined the proportion of LAM-positive participants and conducted modified intent-to-treat analysis excluding LAM-positive participants to determine the effect on 24-week survival, TB incidence and time to TB using Kaplan-Meier method. A5274 enrolled 850 participants, 53% were male and median CD4 count was 18 cells/µL (IQR: 9, 32). Of the 850, 566 (67%) had LAM testing (283 per arm); 28 (5%) were positive [21 (7%); 7 (2%) in empiric and IPT arms, respectively]. Of those LAM-positive, 1 participant in each arm died and 5 of 21 and 0 of 7 in empiric and IPT arms, respectively, developed TB. After excluding these 28 cases, there were 19 and 21 deaths in empiric and IPT arms, respectively (p=0.88). TB incidence remained higher (4.6% vs. 2%, p=0.04) and time to TB remained faster in the empiric arm (p=0.04). Among outpatients with advanced HIV who screened negative for TB by clinical symptoms, microscopy and Xpert testing, LAM testing identified an additional 5% of individuals with TB. . Positive LAM results did not change mortality or TB incidence.</description><identifier>EISSN: 1537-6591</identifier><identifier>PMID: 33638976</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical infectious diseases, 2021-02</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33638976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matoga, Mitch M</creatorcontrib><creatorcontrib>Bisson, Gregory P</creatorcontrib><creatorcontrib>Gupta, Amita</creatorcontrib><creatorcontrib>Miyahara, Sachiko</creatorcontrib><creatorcontrib>Sun, Xin</creatorcontrib><creatorcontrib>Fry, Carrie</creatorcontrib><creatorcontrib>Manabe, Yukari C</creatorcontrib><creatorcontrib>Kumwenda, Johnstone</creatorcontrib><creatorcontrib>Cecilia, Kanyama</creatorcontrib><creatorcontrib>Nyirenda, Mulinda</creatorcontrib><creatorcontrib>Ngongondo, McNeil</creatorcontrib><creatorcontrib>Mbewe, Abineli</creatorcontrib><creatorcontrib>Lagat, David</creatorcontrib><creatorcontrib>Wallis, Carole</creatorcontrib><creatorcontrib>Mugerwa, Henry</creatorcontrib><creatorcontrib>Hosseinipour, Mina C</creatorcontrib><title>Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>The urine lipoarabinomannan (LAM) antigen test is a TB diagnostic test with highest sensitivity in individuals with advanced HIV. Its role in TB diagnostic algorithms for HIV positive outpatients remains unclear. ACTG A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen negative HIV positive adults initiating ART with CD4 counts &lt;50 cells/µL. Retrospective LAM testing was performed on stored urine obtained at baseline. We determined the proportion of LAM-positive participants and conducted modified intent-to-treat analysis excluding LAM-positive participants to determine the effect on 24-week survival, TB incidence and time to TB using Kaplan-Meier method. A5274 enrolled 850 participants, 53% were male and median CD4 count was 18 cells/µL (IQR: 9, 32). Of the 850, 566 (67%) had LAM testing (283 per arm); 28 (5%) were positive [21 (7%); 7 (2%) in empiric and IPT arms, respectively]. Of those LAM-positive, 1 participant in each arm died and 5 of 21 and 0 of 7 in empiric and IPT arms, respectively, developed TB. After excluding these 28 cases, there were 19 and 21 deaths in empiric and IPT arms, respectively (p=0.88). TB incidence remained higher (4.6% vs. 2%, p=0.04) and time to TB remained faster in the empiric arm (p=0.04). Among outpatients with advanced HIV who screened negative for TB by clinical symptoms, microscopy and Xpert testing, LAM testing identified an additional 5% of individuals with TB. . Positive LAM results did not change mortality or TB incidence.</description><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFjssKgkAYRocg0i6vEP8LCMrgbWlhGBRETG1l0rH-0HGYUcG3r6DWrT445yy-CbE9n4ZO4MeeRebGPF3X8yLXnxGL0oBGcRjY5HzRKAUckiMwYTqUd0AJSTlwWYgSsv0VTq3BDgfxpn3dmY_nwDTyGtoK0kahxgLYBthDaK7GJZlWvDZi9d0FWe9Sts0c1d8aUeZKY8P1mP9O0L_BCzYQOwE</recordid><startdate>20210226</startdate><enddate>20210226</enddate><creator>Matoga, Mitch M</creator><creator>Bisson, Gregory P</creator><creator>Gupta, Amita</creator><creator>Miyahara, Sachiko</creator><creator>Sun, Xin</creator><creator>Fry, Carrie</creator><creator>Manabe, Yukari C</creator><creator>Kumwenda, Johnstone</creator><creator>Cecilia, Kanyama</creator><creator>Nyirenda, Mulinda</creator><creator>Ngongondo, McNeil</creator><creator>Mbewe, Abineli</creator><creator>Lagat, David</creator><creator>Wallis, Carole</creator><creator>Mugerwa, Henry</creator><creator>Hosseinipour, Mina C</creator><scope>NPM</scope></search><sort><creationdate>20210226</creationdate><title>Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy</title><author>Matoga, Mitch M ; Bisson, Gregory P ; Gupta, Amita ; Miyahara, Sachiko ; Sun, Xin ; Fry, Carrie ; Manabe, Yukari C ; Kumwenda, Johnstone ; Cecilia, Kanyama ; Nyirenda, Mulinda ; Ngongondo, McNeil ; Mbewe, Abineli ; Lagat, David ; Wallis, Carole ; Mugerwa, Henry ; Hosseinipour, Mina C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_336389763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matoga, Mitch M</creatorcontrib><creatorcontrib>Bisson, Gregory P</creatorcontrib><creatorcontrib>Gupta, Amita</creatorcontrib><creatorcontrib>Miyahara, Sachiko</creatorcontrib><creatorcontrib>Sun, Xin</creatorcontrib><creatorcontrib>Fry, Carrie</creatorcontrib><creatorcontrib>Manabe, Yukari C</creatorcontrib><creatorcontrib>Kumwenda, Johnstone</creatorcontrib><creatorcontrib>Cecilia, Kanyama</creatorcontrib><creatorcontrib>Nyirenda, Mulinda</creatorcontrib><creatorcontrib>Ngongondo, McNeil</creatorcontrib><creatorcontrib>Mbewe, Abineli</creatorcontrib><creatorcontrib>Lagat, David</creatorcontrib><creatorcontrib>Wallis, Carole</creatorcontrib><creatorcontrib>Mugerwa, Henry</creatorcontrib><creatorcontrib>Hosseinipour, Mina C</creatorcontrib><collection>PubMed</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matoga, Mitch M</au><au>Bisson, Gregory P</au><au>Gupta, Amita</au><au>Miyahara, Sachiko</au><au>Sun, Xin</au><au>Fry, Carrie</au><au>Manabe, Yukari C</au><au>Kumwenda, Johnstone</au><au>Cecilia, Kanyama</au><au>Nyirenda, Mulinda</au><au>Ngongondo, McNeil</au><au>Mbewe, Abineli</au><au>Lagat, David</au><au>Wallis, Carole</au><au>Mugerwa, Henry</au><au>Hosseinipour, Mina C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-02-26</date><risdate>2021</risdate><eissn>1537-6591</eissn><abstract>The urine lipoarabinomannan (LAM) antigen test is a TB diagnostic test with highest sensitivity in individuals with advanced HIV. Its role in TB diagnostic algorithms for HIV positive outpatients remains unclear. ACTG A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen negative HIV positive adults initiating ART with CD4 counts &lt;50 cells/µL. Retrospective LAM testing was performed on stored urine obtained at baseline. We determined the proportion of LAM-positive participants and conducted modified intent-to-treat analysis excluding LAM-positive participants to determine the effect on 24-week survival, TB incidence and time to TB using Kaplan-Meier method. A5274 enrolled 850 participants, 53% were male and median CD4 count was 18 cells/µL (IQR: 9, 32). Of the 850, 566 (67%) had LAM testing (283 per arm); 28 (5%) were positive [21 (7%); 7 (2%) in empiric and IPT arms, respectively]. Of those LAM-positive, 1 participant in each arm died and 5 of 21 and 0 of 7 in empiric and IPT arms, respectively, developed TB. After excluding these 28 cases, there were 19 and 21 deaths in empiric and IPT arms, respectively (p=0.88). TB incidence remained higher (4.6% vs. 2%, p=0.04) and time to TB remained faster in the empiric arm (p=0.04). Among outpatients with advanced HIV who screened negative for TB by clinical symptoms, microscopy and Xpert testing, LAM testing identified an additional 5% of individuals with TB. . Positive LAM results did not change mortality or TB incidence.</abstract><cop>United States</cop><pmid>33638976</pmid></addata></record>
fulltext fulltext
identifier EISSN: 1537-6591
ispartof Clinical infectious diseases, 2021-02
issn 1537-6591
language eng
recordid cdi_pubmed_primary_33638976
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A01%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urine%20LAM%20Testing%20in%20Advanced%20HIV%20Positive%20Adults%20in%20a%20Trial%20of%20Empiric%20TB%20Therapy&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Matoga,%20Mitch%20M&rft.date=2021-02-26&rft.eissn=1537-6591&rft_id=info:doi/&rft_dat=%3Cpubmed%3E33638976%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33638976&rfr_iscdi=true